Iterum Therapeutics PLC

Iterum Therapeutics plc announced its ordinary shares will be delisted from Nasdaq and trading suspended on April 1, 2026, following the company's decision to withdraw its appeal and file a winding up petition in Ireland.

Iterum Therapeutics plc has filed a petition in the Irish High Court to wind up the company, leading to the appointment of provisional liquidators and expected dissolution.

Iterum Therapeutics plc has requested a hearing to appeal Nasdaq's delisting determination, facing multiple non-compliance issues and exploring strategic alternatives including potential wind-down.

Iterum Therapeutics plc received a delisting determination from Nasdaq due to non-compliance with minimum bid price and market value requirements, with trading suspension set for March 5, 2026.

Iterum Therapeutics plc received a Nasdaq notice for failing to meet minimum market value, bid price, shareholder equity, and net income requirements, facing potential delisting.

Iterum Therapeutics reported Q3 2025 financial results, highlighted by the commercial launch of ORLYNVAH for uUTIs in August 2025 and an extended cash runway into Q2 2026.

Iterum Therapeutics reported increased net losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern despite the recent U.S. commercial launch of ORLYNVAH.

Iterum Therapeutics reports continued net losses and substantial doubt about its ability to continue as a going concern, while preparing for the commercial launch of ORLYNVAH by end of August 2025.

Iterum Therapeutics reports Q1 2025 results, highlighting ongoing efforts to commercialize ORLYNVAH while addressing concerns about its ability to continue as a going concern.

Iterum Therapeutics announced its Q3 2024 financial results, highlighted by the FDA approval of ORLYNVAH and ongoing strategic evaluation.

Iterum Therapeutics reports a net loss of $12.1 million for the first half of 2024 and expresses substantial doubt about its ability to continue as a going concern due to insufficient cash reserves.

Iterum Therapeutics reports a net loss of $7.1 million for the first quarter of 2024 and expresses substantial doubt about its ability to continue as a going concern due to insufficient cash to fund operations for the next 12 months.

Iterum Therapeutics reports its 2024 financial results and continues to explore strategic alternatives for its approved drug, ORLYNVAH, while addressing going concern uncertainties.

Iterum Therapeutics' 10-K filing details its share capital, regulatory environment, and strategic focus on its sulopenem program.

Iterum Therapeutics plc Director Michael W. Dunne acquired 6,000 ordinary shares at $0.3652 per share, increasing his beneficial ownership.

Iterum Therapeutics plc Director Michael W. Dunne plans to acquire 15,000 ordinary shares at $0.7236 each, increasing his direct holdings to 235,001 shares.

Iterum Therapeutics plc's Chief Commercial Officer, Christine Coyne, was granted 200,000 share options with an exercise price of $0.97, vesting over four years.

Director Ronald Hunt reports the exchange of senior subordinated notes for ordinary shares of Iterum Therapeutics, marking the end of the exchange period for these notes.

Director Michael W. Dunne reports purchasing shares and warrants in Iterum Therapeutics' recent rights offering.

Corey N. Fishman, CEO of Iterum Therapeutics plc, reports the acquisition of ordinary shares and warrants through the company's rights offering.

Iterum Therapeutics plc reminds shareholders to cast their votes for the upcoming Extraordinary General Meeting by February 17, 2026, with the board and ISS recommending 'FOR' all four proposals.

Iterum Therapeutics plc calls an Extraordinary General Meeting to approve critical proposals for capital raising and Nasdaq compliance, warning of potential bankruptcy if not approved.

Iterum Therapeutics plc calls for shareholder approval on critical proposals, including a significant increase in authorized share capital and an amended equity incentive plan, vital for future funding and ORLYNVAH commercialization.

Iterum Therapeutics is urging shareholders to vote in favor of a proposal at the upcoming extraordinary general meeting to allow for more efficient capital raising, critical for the company's future ahead of the PDUFA action date.

Iterum Therapeutics has adjourned its extraordinary general meeting (EGM) to October 8, 2024, to gather more shareholder proxies for a proposal outlined in its August 14, 2024 proxy statement.

Iterum Therapeutics is urging shareholders to vote in favor of a proposal to waive pre-emptive rights on previously authorized shares, which the company says is crucial for its ability to raise capital and continue as a going concern.

Iterum Therapeutics is offering non-transferable subscription rights to existing shareholders and eligible warrant holders to purchase up to 8,503,800 units, aiming to raise approximately $10.3 million.

Iterum Therapeutics is launching a rights offering to raise up to $10.3 million to fund its strategic process and support the review of its New Drug Application (NDA).

Iterum Therapeutics is launching a rights offering to raise up to $ million to fund its strategic process and support its NDA review.

Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in Iterum Therapeutics plc, holding 1,445,158 ordinary shares as of December 31, 2024.